American Journal of Epidemiology Advance Access originally published online on October 5, 2006
American Journal of Epidemiology 2006 164(10):978-983; doi:10.1093/aje/kwj311
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Contribution |
Prostate-specific Antigen Values in Diabetic and Nondiabetic US Men, 2001–2002
1 Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
2 Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
Correspondence to Dr. Mona Saraiya, National Center for Chronic Disease Prevention and Health Promotion, Mail Stop K-55, 4770 Buford Highway NE, Atlanta, GA 30341 (e-mail: msaraiya{at}cdc.gov).
Recent studies have shown that diabetic men have a lower risk of prostate cancer and that this association may be related to time since diagnosis. The authors examined the association between diabetes and prostate-specific antigen (PSA) levels, controlling for potential confounders, in a nationally representative cross-sectional survey of the US population (National Health and Nutrition Examination Survey 2001–2002). Diabetes classification was self-reported, and undiagnosed diabetes was determined with fasting plasma glucose measurements. Controlling for age, men with self-reported diabetes had a 21.6% lower geometric mean PSA level than men without diabetes. The difference increased with years since diagnosis (>10 years: 27.5% lower geometric mean PSA level). Overweight men who had had diabetes for more than 10 years had a predicted geometric mean PSA level 40.8% lower than that of nondiabetic, normal-weight men. These results are consistent with the hypothesis that long-term diabetes is associated with a lower risk of prostate cancer. The mechanism of this association may involve the regulation of PSA by androgens, although the authors are unable to confirm this assertion. Better understanding of the determinants of PSA level is needed to make the distinction between factors affecting the PSA test's accuracy and those altering the risk of prostate cancer.
diabetes mellitus, type 2; prostate-specific antigen; prostatic neoplasms; testosterone
Abbreviations: BMI, body mass index; IGF-1, insulin-like growth factor 1; NHANES, National Health and Nutrition Examination Survey; PSA, prostate-specific antigen
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Wada, K. Kikuchi, H. Kikukawa, and T. Imamura Low serum PSA levels of diabetes mellitus-caused end-stage renal disease patients NDT Plus, February 1, 2008; 1(1): 58 - 59. [Full Text] [PDF]
|
|